A Twelve-Week, Double Masked, Parallel Group, Primary-Therapy Pilot Study of the Safety and Efficacy of Travoprost 0.004% Compared to Pilocarpine 1% in Patients With Chronic Angle-Closure Glaucoma

NCT00762645 Phase 4 COMPLETED Results posted

The purpose of this study is to demonstrate that the Intraocular Pressure (IOP) lowering efficacy of Travoprost Ophthalmic Solution 0.004% is superior to that of Pilocarpine 1% in patients with chronic angle-closure glaucoma (CACG).

Details

Lead sponsor	Alcon Research
Phase	Phase 4
Status	COMPLETED
Enrolment	30
Start date	2007-02
Completion	2008-05

Conditions

• Angle-closure Glaucoma

Interventions

• Travoprost 0.004% (Travatan)
• Pilocarpine 1%

Primary outcomes

• Mean Intraocular Pressure (IOP) — 4PM at Week 12 Visit